Fatigue
Drug research and approvals for fatigue: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 357 studies of fatigue are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, and FDA has 0 approved and 1 open orphan designations naming it.
- Recruiting worldwide: 357
- Trials authorized in Canada: 5
- FDA orphan approvals: 0
- EU medicines: 0
- A Personalised Anti-fatigue Program for Community-dwelling People With Chronic Lymphocytic LeukaemiaNCT07940920 · Not applicable · University of Surrey · starts Dec 1, 2026
- Exploring the Extended Efficacy and Initial Use of RUCONEST® in Managing Neurological Symptoms Linked to Infectious…NCT07932002 · Phase 4 · IMMUNOe Research Centers · starts Nov 5, 2025
- Remote Ischaemic Conditioning for Fatigue After Stroke 2 (RICFAST 2)NCT07914647 · Phase 2 · Sheffield Teaching Hospitals NHS Foundation Trust · starts Apr 16, 2025
- A Clinical Trial to Evaluate the Effects of Adrenal Adapt on Sleep Quality, Daytime Energy, Stress Resilience, and…NCT07893561 · Not applicable · Bioligent · starts Sep 9, 2026
- Recumbent Cycling and Functional Electrical Stimulation for Lower Limb RehabilitationNCT07873424 · Not applicable · National Council of Scientific and Technical Research, Argentina · starts Aug 20, 2026
- Whole-body Cryotherapy in Those With Chronic Fatigue: A Feasibility StudyNCT07874217 · Not applicable · Oxford Brookes University · starts Oct 5, 2026
- Multimodal Machine Learning for Predicting Reduced Participation in Elite Youth FootballNCT07870460 · Not reported · Palacky University · starts Jul 15, 2026
- Cooling During Inpatient Rehabilitation in Persons With MSNCT07852156 · Not applicable · Klinik Valens · starts Jul 28, 2026
- Acute Mental Fatigue and Muscle StrengthNCT07846618 · Not applicable · Florida Institute for Human and Machine Cognition · starts Sep 23, 2026
Approved 1
Phase 3 9
- MethylphenidateDopamine transporter inhibitor
- ModafinilDopamine transporter inhibitor
- ArmodafinilDopamine transporter inhibitor
- DexamethasoneGlucocorticoid receptor agonist
- DocetaxelTubulin inhibitor
- InfliximabTNF-alpha inhibitor
- Epoetin alfaErythropoietin receptor agonist
- ReboxetineNorepinephrine transporter inhibitor
- Acetylcarnitine
Phase 2 6
- Ascorbic acidSupplement
- NaltrexoneOpioid receptors; mu/kappa/delta antagonist
- AnamorelinGhrelin receptor agonist
- ClazakizumabInterleukin-6 inhibitor
- MelatoninMelatonin receptor agonist
- Ginseng, asian
Phase 1 or earlier 3
- DisulfiramAldehyde dehydrogenase inhibitor
- KetamineGlutamate [NMDA] receptor negative allosteric modulator
- AspirinCyclooxygenase inhibitor
How its trials ended
1,457 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 237 whose ending is known, 40% met their primary endpoint, 11% missed it and 49% stopped early.
- Completed, result not reported73550%
- Ongoing27819%
- Status unknown20714%
- Met its primary endpoint957%
- Stopped: other or unclear654%
- Stopped: enrollment or feasibility362%
- Missed its primary endpoint252%
- Stopped: lack of efficacy5<1%
- Stopped: sponsor or business decision5<1%
- Stopped: funding5<1%
- Stopped: safety1<1%
| Apr 24, 2026 | Randomized double-blind placebo-controlled cross over trial of modafinil to treat fatigue in people with mitochondrial disease.Modafinil | Research Institute of The McGill University Health Centre | Pending |
| Mar 7, 2025 | Modafinil to improve fatiguability (MODIFY): modafinil vs. placebo vanguard randomized controlled trialModafinil | Ottawa Hospital Research Institute | Ongoing |
| Feb 26, 2024 | Modafinil and exercise for post stroke fatigue (MODEX)Modafinil | University Health Network | Pending |
| Jan 25, 2023 | Recovering from COVID19 lingering symptoms adaptive integrative medicine (RECLAIM)Oxygen | University Health Network | Ongoing |
| Jun 1, 2022 | A double blind randomized trial of low-dose naltrexone for post-covid fatigue syndromeNaltrexone | British Columbia Womens Hospital | Ongoing |
| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Dec 9, 1993 | Poly I: poly C12UTreatment of chronic fatigue syndrome | AIM ImmunoTech Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA